Atara Biotherapeutics
ATRAAtara Biotherapeutics is a biotechnology company specializing in allogeneic T-cell immunotherapies developed from its Epstein-Barr virus (EBV) T-cell platform.
Table of contents
Earnings
Next report
Aug 10, 2026 (In 1 week)Competitors
By market cap
Profile
Atara Biotherapeutics is a biotechnology company specializing in allogeneic T-cell immunotherapies developed from its Epstein-Barr virus (EBV) T-cell platform. The company focuses on treating patients with cancer and autoimmune diseases through off-the-shelf therapies that leverage the unique immune profile of EBV-specific T cells. Its primary value proposition lies in providing manufactured-in-advance treatments that avoid the logistical complexities of traditional autologous cell therapies.
Atara is a pioneer in allogeneic EBV T-cell therapy with the first-ever EC-approved therapy in this class, though it has recently transitioned from a direct manufacturer to a royalty-and-milestone focused model.
Questions, answered.
- What is Atara Biotherapeutics's market cap?
- Atara Biotherapeutics (ATRA) has a market capitalization of $69.5M and trades on NASDAQ.
- Who are Atara Biotherapeutics's competitors?
- Atara Biotherapeutics's key competitors include Bristol-Myers Squibb, Gilead Sciences, Iovance Biotherapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Atara Biotherapeutics partner with?
- Atara Biotherapeutics's notable partners include Pierre Fabre Medicament, Memorial Sloan Kettering Cancer Center, HealthCare Royalty Partners, and others.
- Where is Atara Biotherapeutics headquartered?
- Atara Biotherapeutics is headquartered in United States of America and employs approximately 173 people. It has been publicly traded since 2014.